154 related articles for article (PubMed ID: 29147383)
1. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
Kapur S; Xiao H; Zakowski MF; Hameed MR; Levin MB
World J Oncol; 2014 Apr; 5(2):81-89. PubMed ID: 29147383
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for progressive metastatic medullary thyroid cancer: a review.
Colombo JR; Wein RO
Ther Clin Risk Manag; 2014; 10():395-404. PubMed ID: 24920914
[TBL] [Abstract][Full Text] [Related]
3. Apatinib-treated advanced medullary thyroid carcinoma: a case report.
Chen K; Gao Y; Shi F; Cao G; Bao J
Onco Targets Ther; 2018; 11():459-463. PubMed ID: 29403290
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.
Viola D; Cappagli V; Elisei R
Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
6. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
7. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen.
Lacin S; Esin E; Karakas Y; Yalcin S
Onco Targets Ther; 2015; 8():1039-42. PubMed ID: 25999738
[TBL] [Abstract][Full Text] [Related]
8. Unusual gastric mucosal infiltration by a medullary thyroid carcinoma: a case report.
Karrasch T; Doppl W; Roller FC; Schäffler A; Schäffer R; Gattenlöhner S
J Med Case Rep; 2016 Jul; 10():208. PubMed ID: 27461534
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
10. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Medullary Thyroid Cancer: A Review.
Priya SR; Dravid CS; Digumarti R; Dandekar M
Front Oncol; 2017; 7():238. PubMed ID: 29057215
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib in the treatment of hepatocellular carcinoma.
B Peters ML; Miksad RA
Future Oncol; 2017 Sep; 13(22):1915-1929. PubMed ID: 28703624
[TBL] [Abstract][Full Text] [Related]
14. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
16. Managing tyrosine kinase inhibitors side effects in thyroid cancer.
Krajewska J; Paliczka-Cieslik E; Jarzab B
Expert Rev Endocrinol Metab; 2017 Mar; 12(2):117-127. PubMed ID: 30063430
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in Thyroid Cancer.
Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
[TBL] [Abstract][Full Text] [Related]
19. [PREOPERATIVE DIAGNOSTICS OF THYROID MEDULLARY CARCINOMA WITH EMPHASIS ON CYTOMORPHOLOGICAL FEATURES AND DIFFERENTIAL DIAGNOSIS OF PRIMARY AND SECONDARY THYROID TUMORS].
Katović SK; Vasilj A
Acta Med Croatica; 2014 Dec; 68(4-5):383-8. PubMed ID: 26285471
[TBL] [Abstract][Full Text] [Related]
20. Putative BRAF activating fusion in a medullary thyroid cancer.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
